BiotechTube

ABP-450 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine

Trial Timeline

Mar 1, 2021 → Aug 6, 2024

NCT ID
NCT04845178

About ABP-450 + Placebo

ABP-450 + Placebo is a phase 2 stage product being developed by AEON Biopharma for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT04845178. Target conditions include Migraine.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT04849988Phase 2Completed
NCT04845178Phase 2Completed

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
ABP-450AEON BiopharmaPhase 2
44
Lasmiditan + PlaceboEli LillyPhase 3
77
Placebo + LY2300559Eli LillyPhase 2
52
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
33
Lasmiditan + PlaceboEli LillyPhase 2
52
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
44
Galcanezumab + ErenumabEli LillyApproved
85
Aricept (donepezil hydrochloride)EisaiPhase 2
52
E2007EisaiPhase 2
52
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
85
Galcanezumab + PlaceboEli LillyPhase 3
77
Lasmiditan + PlaceboEli LillyPhase 2
52
Galcanezumab + PlaceboEli LillyPhase 3
77
LasmiditanEli LillyPhase 3
77
Galcanezumab Prefilled Syringe + PlaceboEli LillyPhase 2
52
Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
85
GalcanezumabEli LillyPre-clinical
23
Galcanezumab + PlaceboEli LillyPhase 3
77
Galcanezumab + PlaceboEli LillyPhase 2
52
LY2590443 + Placebo injection + Sumatriptan + Placebo capsuleEli LillyPhase 2
52

Other Products from AEON Biopharma

ABP-450Phase 2
44
ABP-450 + PlaceboPhase 2
44
ABP-450Phase 2
44